Evidence map›Paper›PMID 38187051›Full record

ReviewAmerican journal of cancer research2023

MicroRNA-183 cluster: a promising biomarker and therapeutic target in gastrointestinal malignancies.

Yufei Zheng, Olga Sukocheva, Edmund Tse, Margarita Neganova, Yulia Aleksandrova, Ruiwen Zhao, Vladimir Chubarev, Ruitai Fan, Junqi Liu

Open access · greenAbstract readReview
In one paragraph

Review in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Yufei ZhengDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
Olga SukochevaDepartment of Hepatology, Royal Adelaide Hospital Adelaide, SA 5000, Australia.
Edmund TseDepartment of Hepatology, Royal Adelaide Hospital Adelaide, SA 5000, Australia.
Margarita NeganovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences Severnij Pr. 1, Chernogolovka 142432, Russia.
Yulia AleksandrovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences Severnij Pr. 1, Chernogolovka 142432, Russia.
Ruiwen ZhaoDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
Vladimir ChubarevSechenov First Moscow State Medical University (Sechenov University) 8-2 Trubetskaya St., Moscow 119991, Russia.
Ruitai FanDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
Junqi LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052, Henan, China.
First Affiliated Hospital of Zhengzhou University · CNA.E. Arbuzov Institute of Organic and Physical Chemistry · RURoyal Adelaide Hospital · AUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small non-coding RNAs (microRNA, miR), powerful epigenetic regulators, were found involved in the regulation of most biological functions via post-translational inhibition of protein expression. Increased expression of pro-oncogenic miRs (known as miR cancer biomarkers) and inhibition of pro-apoptotic miR expression have been demonstrated in different tumors. The recently identified miR-183 was found implicated in gastrointestinal tumor metabolism regulation. Elevated miR-183 expression and cancer-promoting effects were reported in esophageal and colorectal cancers, which was partially contradicted by controversial data observed in gastric cancers. Anti-cancer effect of miR-183 in gastric cancer cells was associated with the Bim-1 and Ezrin genes regulation. Many studies indicated that miR-183 can inhibit tumor suppressor genes in most cell lines, promoting tumor cell proliferation and migration. Increased miR-183 level results in the downregulation of FOXO1, PDCD4, and other tumor suppressor genes in gastrointestinal tumor cells. MiR-183 also influences the signaling of PI3K/AKT/mTOR, Wnt/β-catenin, and Bcl-2/p53 signaling pathways. Mir-183 inhibits apoptosis and autophagy, and promotes epithelial-to-mesenchymal transition, cancer cell proliferation, and migration. Accordingly, gastrointestinal cancer occurrence, development of chemoradiotherapy resistance, recurrence/metastasis, and prognosis were associated with miR-183 expression. The current study assessed reported miR-183 functions and signaling, providing new insights for the diagnosis and treatment of gastrointestinal malignancies.

Indexed as

cancer biomarkerepigeneticsesophageal cancergastrointestinal malignancyMicroRNA (miR)miR-182miR-183miR-96

Identifiers

PMID38187051
PMCPMC10767355
OpenAlexW4390689799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.